Progenity Inc
NASDAQ:PROG
Progenity Inc
NASDAQ:PROG
Price:
0.69 USD
0.01%
Updated:
May 15, 2024
P/S
Price to Sales
Price to Sales
107.7
Current
101.7
Median
2.4
Industry
Higher
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=107.7
Market Cap
/
127.1m
Revenue
1.2m
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| US |
|
Progenity Inc
NASDAQ:PROG
|
127.1m USD | 107.7 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
92.4B EUR | 0.5 | |
| US |
|
Cigna Corp
NYSE:CI
|
98.5B USD | 0.5 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
70.1B USD | 0.2 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
17.8B USD | 1.4 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
16.1B EUR | 0.7 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
15.4B USD | 1.7 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
12.1B EUR | 0.6 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
12B EUR | 0.6 | |
| US |
|
DaVita Inc
NYSE:DVA
|
12B USD | 1 | |
| US |
|
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | 4.4 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
1 271
2-Years Forward
P/S
N/A
3-Years Forward
P/S
N/A
You don't have any saved screeners yet
